The Pharmaceutical Industry and Research in 2020 and Beyond

Drug News and Perspectives

Volumn 16, Issue 10, 2003, Pages 637-648

  Dutta, Anand S ^a   Garner, Andrew ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; ANTITHROMBOCYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIGITALIS; G PROTEIN COUPLED RECEPTOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN; QUININE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROLIPSTATIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VACCINE;

ALLERGIC DISEASE; ARTHRITIS; ASTHMA; BACTERIAL INFECTION; BONE DISEASE; CANCER; CARDIOVASCULAR DISEASE; CELL CYCLE; DIABETES MELLITUS; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; GENE THERAPY; GENOMICS; HUMAN; LEGAL ASPECT; MORALITY; MYCOSIS; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PATENT; PROTEOMICS; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

BIOMEDICAL RESEARCH; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; EFFICIENCY, ORGANIZATIONAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 1042267278     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.10.829294     Document Type: Review

References (73)

1. Dutta, A.S. Discovery of new medicines. In: Textbook of Pharmaceutical Medicine (4th Ed.). J.P. Griffin and J. O'Grady (Eds.). BMJ Books, 2002: 3-95.
2. Dutta, A.S. Small peptides: Chemistry, biology and clinical studies. Elsevier Science Publishers, Amsterdam 1993, 1-616.
3. Ezzati, M., Lopez, A.D., Rodgers, A., Hoorn, S.V., Murray, C.J.L. and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360: 1347-60.
4. Murray, C.J.L. and Lopez, A.D. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global burden of disease study. Lancet 1997, 349: 1347-52.
5. Murray, C.J.L. and Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997, 349: 1436-42.
6. Murray, C.J.L. and Lopez, A.D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349: 1498-504.
7. th century: A period analysis. Lancet 2002, 360: 1131-5.
8. Rx R&D myths: The case against the drug industry's R&D "scare card". Public Citizen's Congress Watch (ISBN 1-58231-024-6; www.citizen.org).
9. Ray, W.A., Stein, C.M., Daugherty, J.R., Hall, K., Arbogast, P.G. and Griffin, M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2003, 60: 1071-3.
10. Sneader, W. The discovery and synthesis of epinephrine. Drug News Perspect 2001, 14: 491-4.
11. Sneader, W. Epinephrine analogues. Drug News Perspect 2001, 14: 539-3.
12. Sneader, W. Histamine and the classic antihistamines. Drug News Perspect 2001, 14: 618-24.
13. Knopp, R.H. Drug therapy: Drug treatment of lipid disorders. New Engl J Med 1999, 341: 498-511.
14. Riggs, B.L. and Hartmann, L.C. Drug therapy: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice. New Engl J Med 2003, 348: 618-29.
15. Jackson, L.M. and Hawkey, C.J. Cox-2 selective nonsteroidal anti-inflammatory drugs. Drugs 2000, 59: 1207-16.
16. 6 receptors in memory formation. Drug News Perspect 2001, 14: 396-400.
17. Ohtsuo, T. and Aoki, Y. N-myristoyltransferase inhibitors as potential antifungal drugs. Drugs Future 2003, 28: 143-52.
18. Dutta, A.S. Goserelin. Drugs Today (Barc) 1987, 23: 545-51.
19. Dutta, A.S., Furr, B.J.A. and Hutchinson, F.G. Zoladex: Discovery, pharmacodynamics and fonnulation. Drug News Perspect 1993, 6: 325-32.
20. Parsons, M.E. and Garner, A. Drug development in gastroenterology: The changing view of industry. Aliment Pharmacol Ther 1995, 9: 457-63.
21. Garner, A., Fadlallah, H. and Parsons, M.E. 1976 and all that! - 20 years of antisecretory therapy. Gut 1996, 39: 784-6.
22. Takacs, L., Vazques-Abad, M-D. and Elliott, E.A. Therapeutic monoclonal antibodies. Ann Rep Med Chem 2001, 36: 237-46.
23. Sela, M., Arnon, R. and Schechter, B. Therapeutic vaccines: Realities of today and hopes for the future. Drug Discov Today 2002, 7: 664-73.
24. Kaushansky, K. Drug therapy: Thrombopoietin. New Engl J Med 1998, 339: 746-54.
25. Goodnough, L.T., Monk, T.G. and Andriole, G.L. Current concepts: Erythropoietin therapy. New Engl J Med 1997, 336: 933-8.
26. Miller, D.H., Khan, O.A., Sheremata, W.A. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2003, 348: 15-23.
27. Swindells, M.B. and Overington, J.P. Prioritising the proteome: Identifying pharmaceutically relevant targets. Drug Discov Today 2002, 7: 516-21.
28. Friedlander, R.M. Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases. New Engl J Med 2003, 348: 1365-75.
29. Ji, T.H., Grossmann, M. and Ji, I. G protein-coupled receptors I. Diversity of receptor-ligand interactions. J Biol Chem 1998, 273: 17299-302.
30. Gether, U. and Kobilka, B.K. G Protein-coupled receptors - II. Mechanism of agonist activation. J Biol Chem 1998, 273: 17979-82.
31. Morris, A.J. and Malbon, C.C. Physiological regulation of G protein-linked signalling. Physiol Rev 1999, 79: 1373-430.
32. Stadel, J.M., Wilson, S. and Bergsma, D.J. Orphan G protein-coupled receptors: A neglected opportunity for pioneer drug discovery. Trends Pharmacol Sci 1997, 18: 430-7.
33. Wilson, S., Bergsma, D.J., Chambers, J.K. et al. Orphan G-protein-coupled receptors - The next generation of drug targets. Br J Pharmacol 1998, 125: 1387-92.
34. Drews, J. Drug discovery: A historical perspective. Science 2000, 287: 1960-4.
35. Trivedi, B.K., Low, J.E., Carson, K. and LaRosa, G.J. Chemokines: Targets for novel therapeutics. Ann Rep Med Chem 2000, 35: 191-200.
36. Osborne, C.K., Zhao, H. and Fuqua, S.A.W. Selective oestrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000, 18: 3172-86.
37. Mitlak, B.H. and Cohen, F.J. Selective oestrogen receptor modulators. Drugs 1999, 57: 653-63.
38. Agnusdei, D. and Iori, N. Selective oestrogen receptor modulators (SERMs): Effects on multiple organ systems. Curr Med Chem 2000, 7: 577-84.
39. Zhi, L. and Martinborough, E. Selective androgen receptor modulators. Ann Rep Med Chem 2001, 36: 169-80.
40. Sedlacek, H.H. Kinase inhibitors in cancer therapy. Drugs 2000, 59: 435-76.
41. Favoni, R.E. and De Cupis, A. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev 2000, 52: 179-206.
42. Noonberg, S.B. and Benz, C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 2000, 59: 753-67.
43. Toledo, L.M., Lydon, N.B. and Elbaum, D. The structure based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999, 6: 775-805.
44. Brooks, G. and La Thangue, N.B. The cell cycle and drug discovery: The promise and the hope. Drug Discov Today 1999, 4: 455-64.
45. Morin, M.J. From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents. Oncogene 2000, 19: 6574-83.
46. Planel, E., Sun, X. and Takashima, A. Role of GSK-3beta in Alzheimer's disease pathology. Drug Dev Res 2002, 56: 491-510.
47. Pollack, S.J. and Harper, S.J. Trk neurotrophin receptor activators. Drug News Perspect 2002, 15: 268-77.
48. Matter, A. Tumour angiogenesis as a therapeutic target. Drug Discov Today 2001, 6: 1005-23.
49. Savage, D.G. and Antman, K.H. Drug therapy: Imatinib mesylate - A new oral targeted therapy. New Engl J Med 2002, 346: 683-93.
50. Slamon, D.J., Leyland-Jones, B., Shak, S. et. al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344: 783-92.
51. Burke, W. Genomic medicine: Genetic testing. New Engl J Med 2002, 347: 1867-75.
52. Khoury, M.J., McCabe, L.L. and McCabe, E.R.B. Genomic medicine: Population screening in the age of genomic medicine. New Engl J Med 2003, 348: 50-8.
53. Evans, W.E. and McLeod, H.L. Drug therapy: Pharmacogenomics - drug disposition, drug targets, and side effects. New Engl J Med 2003, 348: 538-49.
54. Beeley, L.J., Duckworth, M. and Southan, C. The impact of genomics on drug discovery. Prog Med Chem 2000, 37: 1-43.
55. Persidis, A. The business of pharmacogenomics. Nat Biotechnol 1998, 16: 209-10.
56. Nussbaum, R.L. and Ellis, C.E. Genomic medicine: Alzheimer's disease and Parkinson's disease. New Engl J Med 2003, 348: 1356-64.
57. Kaneko, S., Okada, M., Iwasa, H., Yamakawa, K. and Hirose, S. Genetics of epilepsy: Current status and perspectives. Neurosci Res 2002, 44: 11-30.
58. Tournier-Lasserve, E. New players in the genetics of stroke. New Engl J Med 2002, 347: 1711-2.
59. Blackstock, W.P. and Weir, M.P. Proteomics: Quantitative and physical mapping of cellular proteins. Trends Biotechnol 1999, 17: 121-7.
60. Betz, S.F., Baxter S.M. and Fetrow, J.S. Function first: A powerful approach to post-genomic drug discovery. Drug Discov Today 2002, 7: 865-71.
61. Chambers, S.P. High-throughput protein expression for the post-genomic era. Drug Discov Today 2002, 7: 759-65.
62. Stewart, L., Clark, R. and Behnke, C. High-throughput crystallization and structure determination in drug discovery. Drug Discov Today 2002, 7: 187-96.
63. Harris, C.C. and Hollstein, M. Medical progress: Clinical implications of the p53 tumour-suppressor gene. New Engl J Med 1993, 329: 1318-27.
64. Lane, D.P and Hupp, T.R. Drug discovery and p53. Drug Discov Today 2003, 8: 347-55.
65. Floyd, C.D., Leblanc, C. and Whittaker, M. Combinatorial chemistry as a tool for drug discovery. Prog Med Chem 1999, 36: 91-168.
66. Cox, B., Denyer, J.C., Binnie, A. et al. Application of high-throughput screening techniques to drug discovery. Prog Med Chem 2000, 37: 83-133.
67. Walters, W.P., Stahl, M.T. and Murcko, M.A. Virtual screening - an overview. Drug Discov Today 1998, 3: 160-78.
68. Lin, J.H. and Lu, A.Y.H. Role of pharmacokinetics and metabolism in drug discovery and metabolism. Pharmacol Rev 1997, 49: 403-49.
69. Beresford, A.P., Selick H.E. and Tarbit, M.H. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today 2002, 7: 109-16.
70. Gilman, S. Medical progress: Imaging the brain. New Engl J Med 1998, 338: 812-20, 889-98.
71. Aboagye, E.O., Price, P.M and Jones, T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 2001, 6: 293-302.
72. van Tinteren, H. et al. and the PLUS study group. Effectiveness of positron emission tomography in the pre-operative assessment of patients with suspected non-small cell lung cancer: The PLUS multicentre randomised trial. Lancet 2002, 359: 1388-92.
73. Contag, P.R. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov Today 2002, 7: 555-62.